Dendritic Cell Vaccine

Phase 3Vaccine

HH. Lee Moffitt Cancer Center and Research Institute

Dendritic Cell Vaccine is one of 168 biologic programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

167

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Leptomeningeal DiseaseActive, not recruiting

HIVRecruiting

Neoadjuvant TherapyRecruiting

GlioblastomaNot yet recruiting

NeoantigenRecruiting

Breast CancerPhase 1

Active, not recruiting

Leptomeningeal DiseasePhase 1

Active, not recruiting

HIVPhase 2

Recruiting

Neoadjuvant TherapyPhase 1

Recruiting

GlioblastomaPhase 3

Not yet recruiting

NeoantigenPhase 1

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Dendritic Cell Vaccine

HH. Lee Moffitt Cancer Center and Research Institute

Phase 3

1 2

Adenocard

Astellas

Preclinical

2 3

Voltaren

Novartis

Preclinical

1 4

Lexiscan

Astellas

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 9

Duragesic-100

CCephalon

Preclinical

2 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Leptomeningeal Disease

NCT05809752

Q2 2028

Phase 2Recruiting

HIV

NCT06805656

Q1 2029

Phase 3Not yet recruiting

Glioblastoma

NCT06749925

Q2 2029

Phase 1Recruiting

Neoadjuvant Therapy

NCT06435351

Clinical

Trials by Indication[1]

Malignant Glioma2 trials

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

Completed·MMacarena De La Fuente, MD·Phase 1·NCT01808820·20 enrolled

Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients

Completed·—·Phase 1·NCT00576446·35 enrolled

Melanoma1 trial

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Unknown status·KKarolinska University Hospital·Phase 1·NCT01946373·20 enrolled

Prostate Cancer1 trial

Vaccine Therapy in Curative Resected Prostate Cancer Patients

Unknown status·OOslo University Hospital·Phase 1/2·NCT01197625·30 enrolled

Immune Response1 trial

Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00700167·43 enrolled

Neoantigen1 trial

Neoantigen Derived DCs as Cancer Treatment

Recruiting·NNational Health Research Institutes, Taiwan·Phase 1·NCT05767684·12 enrolled

14 more indications

Antiretroviral Treatment1 trial

Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial)

Completed·—·Phase 1·NCT00796770·19 enrolled

Leukemia1 trial

Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias

Withdrawn·JJuan C. Ramos, MD·Phase 1·NCT05321940

Metastatic Colorectal Cancer1 trial

Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer

Completed·FFundacion Clinic per a la Recerca Biomédica·Phase 2·NCT01413295·52 enrolled

HIV-11 trial

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

Completed·FFederal University of São Paulo·N/A·NCT02961829·30 enrolled

HIV-1 infection1 trial

Dendritic Cell Vaccine in HIV-1 Infection

Completed·HHospital Clinic of Barcelona·Phase 1/2·NCT00402142·60 enrolled

Head and Neck Cancer1 trial

Dendritic Cell Vaccine for Head and Neck Cancer

Withdrawn·UUniversity of Maryland, Baltimore·Phase 1·NCT00492947

Glioblastoma1 trial

Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma

Not yet recruiting·UUniversity of Sao Paulo General Hospital·Phase 3·NCT06749925·186 enrolled

Pediatric Brain Tumor1 trial

Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors

Terminated·EEdward Ziga·Phase 1·NCT01902771·1 enrolled

Neoadjuvant Therapy1 trial

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06435351·16 enrolled

Breast Cancer1 trial

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03387553·31 enrolled

Glioblastoma Multiforme1 trial

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

Completed·—·Phase 2·NCT00323115·11 enrolled

HER2-positive Breast Cancer1 trial

Phase 1 Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients With Metastatic HER2-Positive Breast Cancer

Suspended·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05378464·28 enrolled

Leptomeningeal Disease1 trial

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05809752·15 enrolled

HIV1 trial

Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Use of Antiretrovirals

Recruiting·FFederal University of São Paulo·Phase 2·NCT06805656·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Dendritic Cell Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dendritic Cell Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dendritic Cell Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — H. Lee Moffitt Cancer Center and Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: HH. Lee Moffitt Cancer Center and Research Institute

Dendritic Cell Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Q1 2029

Q2 2029

Trials by Indication[1]

Malignant Glioma2 trials

Melanoma1 trial

Prostate Cancer1 trial

Immune Response1 trial

Neoantigen1 trial

Antiretroviral Treatment1 trial

Leukemia1 trial

Metastatic Colorectal Cancer1 trial

HIV-11 trial

HIV-1 infection1 trial

Head and Neck Cancer1 trial

Glioblastoma1 trial

Pediatric Brain Tumor1 trial

Neoadjuvant Therapy1 trial

Breast Cancer1 trial

Glioblastoma Multiforme1 trial

HER2-positive Breast Cancer1 trial

Leptomeningeal Disease1 trial

HIV1 trial

References

Drug Info

Quick Facts

Related News